Last reviewed · How we verify
NCT06203795: PATENCY
Dialysis Performance of the FX CorAL Membrane
NA trial testing Anticoagulation dosing in Hemodialysis Complication in 10 participants. Completed in 1 December 2024.
26 October 2023
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 2 October 2023 |
| Primary completion | 26 October 2023 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Anticoagulation dosing
- Blood sampling — full drug profile →
- Duration of the dialysis session
- Choice of the hemodialyzer
Conditions studied
- Hemodialysis Complication — all drugs for Hemodialysis Complication →
- Anticoagulants — all drugs for Anticoagulants →
Sponsor
University Hospital, Ghent
Who can join
18 and older, any sex, with Hemodialysis Complication or Anticoagulants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anticoagulation remains an important issue in the setting of hemodialysis, and up till now there are some major points on which further research is needed. First, it is important to have a portfolio of the performance of different commercially available dialyzers with respect to fiber clotting. Second, to better estimate the impact of clotting on the overall dialysis performance, clotting kinetics during dialysis should be understood. The aim of the present project is therefore to quantify the performance of the FX CorAL dialyzer (Fresenius Medical Care, Germany) in settings with reduced anticoagulation, and compare different performance outcomes (percent open fibers, solute removal rates) to those of other commercially available dialyzers. The different outcomes are related to the dialyzer extraction ratio and reduction ratio of small and middle molecules and albumin, the visual scoring of the dialyzer post dialysis, and the anticoagulation properties as assessed by fiber blocking in the dialyzer. Performance parameters at different time steps will allow to better understand clotting kinetics during dialysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06203795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemodialysis Complication
Currently open trials in the same condition.
- NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
- NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
- NCT07047547 — A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure · NA · recruiting
- NCT06452563 — Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients · Phase 4 · active not recruiting
- NCT06520631 — Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients · NA · recruiting
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06203795 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06203795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing